Investment Rating - The investment rating for Sunny Optical is maintained at Neutral with a target price of HK$83.1, representing an upside potential of 24.4% from the current price of HK$66.80 [13][12][8] Core Insights - The report highlights a muted month-over-month growth in May shipments across various product lines, with handset lens shipments down 5% month-over-month and year-over-year to 98 million units [1][7] - Camera module shipments decreased by 17% year-over-year and 4% month-over-month to 38 million units, attributed to a strategic shift towards mid/high-end projects [1][8] - Vehicle lens shipments showed a year-over-year increase of 28% but a month-over-month decline of 7%, totaling 11 million units in May, driven by growing client demand [1][7] Shipment Summary - Handset lens shipments for the first five months of 2025 (5M25) totaled 498 million units, reflecting a 5% year-over-year decline, tracking 81% of previous first-half estimates [7][8] - Vehicle lens shipments in 5M25 reached 54 million units, marking an 18% year-over-year increase, consistent with 86% of prior estimates [7][8] - Camera module shipments in 5M25 were 186 million units, down 25% year-over-year, tracking 81% of previous estimates, which is lower than the 86% tracked in the same period last year [8][7] Financial Projections - Revenue projections for Sunny Optical indicate a gradual increase from RMB 38.3 billion in 2024 to RMB 56.5 billion by 2027, with net income expected to rise from RMB 2.7 billion in 2024 to RMB 4.8 billion in 2027 [9][13] - The report anticipates a target P/E multiple of 21.0x for 2026, aligning with the company's historical trading range [12][8] Market Context - The report notes competitive pressures in the handset lens market and varying shipment growth expectations for camera modules, which could impact market share and operational efficiency [12][8]

Investment Rating - The investment rating for Laopu Gold is Equal-weight [5][6]. Core Insights - Recent demand in the second quarter to date remains healthy for both promotional and normal seasons, despite a recent decline and stabilization in gold prices [8]. - The company plans to open a new store in Singapore in late June 2025, expecting it to be one of the top-performing stores within its network [3]. - Laopu Gold aims to increase the mix of antique products, which currently account for 20% of total sales, with an average selling price (ASP) of over Rmb100,000 compared to approximately Rmb30,000 for regular jewelry [2][8]. Summary by Sections New Product Launches - Multi-color enamel Hulu necklaces launched on May 30 are well received among core customers, enhancing brand recognition [2]. Store Expansion Plans - There could be one or two additional store openings in 2025, with a target total of eight stores [8]. - New store locations include IFC and Xintiandi in Shanghai, MixC in Shenzhen Bay, IFC in Hong Kong, and Marina Bay Sands in Singapore [8]. Pricing Strategy - A price hike is anticipated after the 618 festival, with the exact timing still uncertain, but a potential increase in September 2024 is noted [2][8]. Financial Projections - The price target is set at HK$865.00, with a projected P/E ratio of 33x for 2025, indicating a PEG of 1.4, aligning with the overall Chinese consumer average [10].

Investment Rating - The report maintains an "Overweight" rating for Kingsoft Cloud with a target price of $18.50 for KC US and HKD 10.00 for 3896 HK [1][2][16] Core Insights - Kingsoft Cloud's stock price has increased by 140% since the release of its Q3 2024 results, outperforming the Chinese internet index fund which rose by 8% during the same period [1][12] - The company's strategic shift towards artificial intelligence and its integration within the Xiaomi and Kingsoft Group ecosystems are yielding positive financial results [1][12] - The growth prospects for Kingsoft Cloud's AI revenue are considered more certain compared to many other AI stocks due to its unique relationships and increasing demand for GPU computing power [1][12] - The introduction of third-party computing providers is expected to negatively impact Kingsoft Cloud's profit margins due to the complexities in supply chain management [1][12] Summary by Sections Investment Thesis - Kingsoft Cloud's AI revenue has shown significant growth, with total AI revenue rising from RMB 360 million in Q3 2024 to RMB 474 million in Q4 2024 (approximately 500% year-on-year) and RMB 530 million in Q1 2025 (228% year-on-year) [3][12] - The company has achieved three consecutive quarters of triple-digit year-on-year growth in AI revenue, which has improved overall profitability, with adjusted EBITDA margins increasing from 2% in Q1 2024 to 16% in Q1 2025 [3][12] Financial Projections - Revenue forecasts for 2025 have been raised to RMB 9,355 million, reflecting a 17% increase from previous estimates [4][16] - Adjusted net loss for 2025 is projected to be RMB 874 million, revised from RMB 602 million due to the new computing procurement model [4][12] - The target price is based on a 4x EV/Sales multiple for 2025, positioned between the average multiples of U.S. single-business cloud service providers (5.9x) and small-cap SaaS stocks (3.8x) [8][12] Valuation - The target price for Kingsoft Cloud is set at $18.50 based on a 4x EV/Sales multiple for 2025, reflecting a positive adjustment in valuation due to the company's narrative shift [1][8][12] - The report indicates that Kingsoft Cloud's valuation should be adjusted upwards due to the positive changes in the company's narrative and financial performance [1][12]

Investment Rating - The report assigns an "Overweight" (OW) rating to Akeso with a price target of HK$99.00 by December 2025 [2][5]. Core Insights - Akeso's AK104, a PD-1/CTLA-4 bispecific antibody, has received approval in China for first-line treatment of persistent, recurrent, or metastatic cervical cancer, which is expected to significantly boost sales in China [1][4]. - The report anticipates a global development plan for AK104 to be announced in the second half of 2025, which could attract investor interest [1][4]. - Upcoming catalysts include sales figures for AK104 and AK112, the potential global development plan announcement, and detailed data from the HARMONi studies [4][5]. Summary by Sections Approval and Efficacy - AK104's approval is based on strong results from the Phase 3 COMPASSION-16 study, showing a median overall survival (mOS) not reached in the AK104+chemo cohort compared to 22.8 months in the control group, and a median progression-free survival (mPFS) of 12.7 months versus 8.1 months [4]. Market Potential - The report estimates that AK104 could generate approximately RMB 6 billion in peak sales in China, while AK112 is expected to achieve over RMB 5 billion in peak sales in non-small cell lung cancer (NSCLC) [5]. Valuation - The price target of HK$99.00 is based on a discounted cash flow (DCF) valuation, assuming a terminal growth rate of 3.0% and a weighted average cost of capital (WACC) of 9.4% [6].

Investment Rating - The report maintains a Neutral rating for HUTCHMED (HCM) with a 12-month price target of $18 for the ADR listed in the US, indicating a potential upside of 32.4% from the current price of $13.60 [12][14]. Core Insights - Increased investor focus is expected on savolitinib following data presentations at ASCO, with the company highlighting severe under-detection of MET amplification when using NGS testing compared to FISH testing [1][2]. - The company’s internal unpublished data suggests that only about 30% of patients who test positive for MET amplification via FISH would also test positive using the NGS method [2]. - The global Phase 3 SAFRON study of savolitinib in combination with osimertinib will offer patients the option of two companion diagnostics: FISH and IHC methods [2]. Summary by Sections MET Amplification Testing - Testing for MET amplification is crucial for patient selection, with a cross-study analysis indicating that NGS testing severely under-detects the biomarker compared to FISH [2]. - The MARIPOSA-2 study detected MET amplification in 14% of patients using ctDNA NGS, while the SACHI study showed approximately 30% detection using tissue FISH [5]. Clinical Efficacy - The SACHI study demonstrated a median progression-free survival (PFS) of 8.2 months for the savolitinib plus osimertinib combination compared to 4.5 months for chemotherapy, with a statistically significant hazard ratio of 0.34 [5][6]. - For patients previously treated with a 3rd-generation EGFR TKI, the median PFS was 6.9 months for the combination arm versus 3.0 months for chemotherapy, also showing a significant difference [6]. Safety Profile - The SAVANNAH study indicated a promising PFS curve separation with a manageable safety profile, although adverse events leading to dose interruption of savolitinib occurred in approximately 48% of patients [9].

Investment Rating - The report maintains an "Overweight" rating on Zai Lab (ZLAB) shares, indicating a positive outlook on the stock's performance relative to its peers [2][4]. Core Insights - The ZL-1310 ASCO phase 1a/1b update demonstrates a compelling efficacy and safety profile, highlighting its differentiated potential in treating extensive-stage small cell lung cancer (ES-SCLC) [4]. - The 1.6 mg/kg cohort shows a 79% unconfirmed overall response rate (ORR) and a 100% disease control rate (DCR) in patients with one prior line of therapy, suggesting strong efficacy [4]. - The report anticipates that Zai Lab will initiate a pivotal trial in second-line SCLC later this year, which could further validate the drug's potential [4]. - The report estimates that assuming approximately $500 million in net sales/royalties to Zai Lab, this could add mid-single digits to the valuation of ZLAB shares [4]. Summary by Sections Efficacy and Safety Profile - The ZL-1310 trial data indicates a 67% unconfirmed ORR and a 97% DCR in the overall population of 33 patients [4]. - The safety profile is described as clean, with no discontinuations and Grade 3+ treatment-related adverse events (TRAEs) at 6%, primarily consisting of anemia (2%) and neutropenia (4%) [4]. Competitive Landscape - The report notes that Imdelltra (tarlatamab) has a ~40% ORR in relapsed/refractory ES-SCLC, positioning ZL-1310 favorably in comparison [4]. Future Outlook - Zai Lab's existing commercial franchise and upcoming product launches, along with a growing internal pipeline including ZL-1310, support the reiterated Overweight rating [4].

Investment Rating - The report maintains a "Buy" rating for Miniso, with a 12-month price target of $23.10 for ADR and HK$45.00 for H-share, indicating an upside potential of 34.5% and 33.7% respectively [14][17]. Core Insights - Miniso is expected to experience sequential sales growth acceleration, with management confident in margin improvement and a peak in DTC-related expenses in the first half of the year [1][2]. - Same-store sales growth (SSSG) turned positive in May for Miniso China, and positive trends were also observed in the US and other overseas markets [1][7]. - The company plans to enhance its product offerings, focusing on both intellectual property (IP) products and value-for-money lifestyle products, with localized designs for overseas markets [1][10]. - Management aims to expand to over 1,000 stores in the US market, targeting a 20% operating profit margin in the mid to long term, despite potential short-term volatility [1][11]. Summary by Sections Sales Growth and Guidance - For Q2 2025, Miniso China is expected to achieve low teens percentage sales growth, while Miniso Overseas and Top Toy are projected to grow by 25%-30% and 70%-80% year-over-year respectively [8]. - If the SSSG recovery trend continues, operating profits are likely to turn positive in Q3, with full-year adjusted operating profits targeted at RMB 3.6 billion to RMB 3.8 billion [8]. Product Strategy - The company is enhancing its IP product quality and focusing on localized designs for international markets, while also improving the merchandising of value-for-money products [10][12]. - A dedicated zone for top-selling products has been added to increase conversion rates, and inventory management will be prioritized to avoid stockouts of best-sellers [11]. Market Performance - Year-to-date, Miniso China's SSSG has shown improvement, with positive trends in the US market and other overseas markets noted in April and May [7][11]. - The US market has seen the opening of approximately 20 new stores, primarily in plaza locations, achieving double-digit operating profit margins despite being in a low season [11]. Long-term Outlook - Miniso is positioned to become a leading global IP retailer, with catalysts for share price growth including accelerated store expansion, improved SSSG, and higher contributions from IP products [14]. - The market currently underappreciates Miniso's potential adjusted net income compound annual growth rate (CAGR) of nearly 20% from 2024 to 2026, excluding contributions from Yonghui [14].

Investment Rating - The report maintains an "Overweight" (OW) rating for Laopu Gold with a price target of HK$1,149.00 for December 2025, up from a prior target of HK$1,111.00 [4][26]. Core Insights - Laopu Gold is positioned as a niche luxury brand in the China heritage gold sector, with a market share of 2% as of 2023 and a strong focus on tier 1 and new tier 1 cities, which account for over 85% of its sales [10][26]. - The company is expected to achieve a compound annual growth rate (CAGR) of 61% in sales and 68% in net profit from 2025 to 2027, driven by the growth of the heritage gold segment, store expansion, and enhanced brand equity [10][26]. - Laopu plans to open at least eight new boutiques in 2025, surpassing the seven opened in 2024, and will continue refreshing existing boutiques [7][10]. Summary by Sections Sales and Revenue Projections - Revenue estimates for 2025 have been raised from Rmb 18,780 million to Rmb 19,973 million, and for 2026 from Rmb 26,172 million to Rmb 28,061 million [5]. - The company targets mid-term sales per shopping mall to reach Rmb 1 billion by 2025, significantly higher than the Rmb 300 million expected in 2024 [10]. Boutique Expansion and Strategy - Laopu's expansion strategy includes opening its first overseas boutique in Singapore and a differentiated product offering in Tokyo targeting non-Chinese customers [10][26]. - The company plans to refresh at least four existing boutiques in 2025, maintaining the same level as in 2024 [7][10]. Market and Pricing Dynamics - Laopu's management is optimistic about the upward trend in gold prices, with expectations of a 41% increase in 2025 and 21% in 2026, which will support further penetration into target consumer groups [7][20]. - The company has implemented a price adjustment policy to maintain a gross profit margin (GPM) target of over 40%, with expectations of 1-2 additional price increases in 2025 [7][10]. Financial Metrics and Valuation - The report projects a significant increase in adjusted earnings per share (EPS) from Rmb 9.47 in 2025 to Rmb 24.14 in 2026, reflecting a growth rate of 154.8% [9][10]. - The DCF-based price target of HK$1,149 implies a forward P/E ratio of 32x for 2025 [27]. Performance Drivers - Laopu's strong performance is attributed to its high single-store sales, pricing premium over local brands, and a robust retail experience that enhances customer loyalty [10][26]. - The company is expected to benefit from a favorable product mix and operational leverage, leading to a net margin expansion of 1.5 percentage points in 2025 [13].

Investment Rating - The report assigns a "Buy" rating for CSPC Pharma with a 12-month price target of HK$8.74, indicating an upside potential of 14.7% from the current price of HK$7.62 [13][14]. Core Insights - The report highlights that CSPC Pharma experienced a revenue decline of 22% in Q1, primarily due to a high base in Q1 2024, ongoing pressure from volume-based procurement (VBP), and a 12.5% price cut for NBP injection [1]. - Despite the revenue miss, earnings showed resilience, supported by out-licensing income and significant expense cuts, particularly in selling expenses [1]. - Management has revised its guidance for 2025, focusing on sequential improvement rather than positive sales growth, and plans to pursue three more business development (BD) deals with a potential total deal size exceeding US$5 billion [2][8]. Summary by Sections Revenue and Earnings Performance - CSPC Pharma's sales in Q1 declined by 22% year-on-year, with finished drug sales down 27% year-on-year [1]. - Earnings for Q1 were reported at Rmb1.5 billion, an 8% decrease year-on-year, but were bolstered by Rmb718 million from out-licensing [1]. - Core earnings, excluding BD income, are estimated to have declined by approximately 45% year-on-year [1]. Business Development and Licensing - The company is actively negotiating three potential BD deals, with one expected to close in June, focusing on SYS6010 (EGFR ADC) and other technology collaborations [2]. - In Q1, CSPC Pharma booked US$40 million from the AZ deal and US$60 million from the BeOne deal, with expectations of over Rmb1 billion in additional income from new deals throughout the year [2]. Clinical Development and Pipeline - SYS6010 is prioritized for clinical development, with ongoing phase 3 studies for NSCLC and plans for further trials in various solid tumors [3][7]. - The company is preparing for pivotal studies outside China and aims to apply for breakthrough designation for certain assets [7]. Shareholder Returns and Incentives - CSPC Pharma plans to utilize operational cash flow for R&D and higher dividends, with a share buyback target of up to HK$5 billion over the next 24 months [8]. - A share-based incentive program is set to cover 200-300 key staff, with additional coverage planned for the second half of 2025 [8]. Financial Projections - Earnings estimates have been revised down by 7.7% for 2025 due to lower-than-expected finished drug sales, but the price target has increased from HK$7.84 to HK$8.74 [9]. - Revenue projections for 2025 are set at Rmb30.1 billion, with expectations of gradual recovery in subsequent years [14].

Investment Rating - The report maintains a "Buy" rating for Miniso, with a 12-month price target of $23.40 for ADR and HK$46.00 for H-share, indicating an upside potential of 27.9% and 33.1% respectively [14][17]. Core Insights - Management is confident in achieving revenue growth acceleration in 2025, targeting a year-over-year increase of 23% compared to 2024, with a focus on low teens percentage growth in Miniso China and around 40% growth in overseas markets [1][8]. - Despite expected margin pressure in the short term, management anticipates a return to positive operating profit growth by the third quarter of 2025, with a narrowing of margin contraction [1][2]. - The company plans to close 300-400 underperforming stores in China, with expectations of a return to net store count growth in the second half of 2025 [1][12]. Summary by Sections Financial Performance - For 2025, Miniso aims for revenue of Rmb20,554 million, with an operating profit (OP) target of Rmb3.6 billion to Rmb3.8 billion, compared to Rmb3.2 billion in the previous year [17]. - In 2Q25, management expects topline growth of 18%-21%, with specific growth rates of low teens for Miniso China and 25%-30% for overseas markets [8]. Market Strategy - The company is focusing on optimizing its product offerings in the US, with IP-related products making up 60-70% of sales, and plans to increase local sourcing to mitigate tariff impacts [12][15]. - Miniso's store expansion strategy includes targeting 80-100 net new store openings in 2025, with a significant portion being DTC stores [10][11]. Operational Efficiency - Management noted that logistics costs have declined, and there is potential for cost savings through improved store productivity and geographical concentration of store openings [10][12]. - The average payback period for new stores is reported to be 15-18 months, with daily sales averaging nearly Rmb10,000, significantly above the breakeven point [13].